Individuals whose families meet the Amsterdam II clinical criteria for hereditary non-polyposis colorectal cancer are recommended to be referred for genetic counseling and to have colonoscopic screening every 1-2 years. To assess the uptake and knowledge of guideline-based genetic counseling and colonoscopic screening in unaffected members of families who meet Amsterdam II criteria and their treating endoscopists.
INTRODUCTION
Lynch syndrome is an autosomal dominant disorder accounting for~2-4% of all colorectal cancers (CRCs) and is associated with a 50-80% lifetime risk of developing CRC ( 1 ) .
Th e Amsterdam II ( 2 ) family history criteria for hereditary non-polyposis colorectal cancer (HNPCC) are used to identify individuals who are at increased risk for Lynch syndrome. Th ese criteria include the following: three biological relatives with CRC or another Lynch-associated cancer (endometrial, ovarian, upper urinary tract, small bowel) who are linked through a fi rst-degree relative; at least two consecutive generations aff ected; and one cancer diagnosis under the age of 50.
Professional society guidelines (3) (4) (5) (6) (7) (8) recommend off ering genetic counseling to all individuals who meet Amsterdam II criteria. According to these guidelines, Lynch syndrome mutation carriers and age-eligible individuals who meet Amsterdam II criteria who have not undergone genetic testing should undergo colonoscopy every 1 to 2 years starting at age [20] [21] [22] [23] [24] [25] .
Although aggressive screening in Lynch syndrome has shown to reduce CRC incidence and mortality ( 9 ) , individuals at risk for Lynch syndrome are grossly under-recognized. Hampel and Chapelle ( 10 ) estimated that only ~10,000 of the projected 830,000 individuals (1.2%) in the United States with Lynch syndrome are aware of their mutation status. Some possible reasons for failure to identify Lynch syndrome families include incomplete ascertainment of multi-generation family history data, lack of recognition that an individual meets Amsterdam II criteria, limited sensitivity of Amsterdam II criteria for diagnosing Lynch syndrome, and cumbersome predictive models used clinically to assess CRC risk.
Even when Lynch syndrome is suspected or confi rmed, the reported compliance rates for CRC screening are widely variable (53-100%) (11) (12) (13) (14) (15) (16) . Th ese projections are likely overestimates as most studies included highly selected patient populations from genetics clinics and are oft en considered "compliant" if they participate in a single screening test or who have "ever been screened. " A lack of knowledge regarding recommended screening guidelines among patients as well as providers has been identifi ed as potential barriers to appropriate guideline-based screening ( 17, 18 ) .
Th ere are limited data regarding knowledge and uptake of genetic counseling and colonoscopic screening recommendations for CRC-unaff ected individuals who meet Amsterdam II criteria, especially those individuals who may not be aware that they are at risk of Lynch syndrome. Further, little is known about what screening intervals endoscopists who care for these patients recommend and how these compare with what patients understand. We hypothesized that there is poor knowledge and uptake of genetic counseling and colonoscopic screening among patients unaff ected by CRC who meet the Amsterdam II criteria and their providers and that this is more pronounced in individuals identifi ed in the general population as compared with those whose families have sought care at high-risk cancer clinics.
Th e aims of this study were as follows: (i) to evaluate the knowledge and uptake of genetic counseling and testing and the knowledge of risk-appropriate colonoscopic screening among CRC-unaff ected members of families who meet Amsterdam II criteria recruited from both high-risk cancer clinics, as well as population-based registries, (ii) to evaluate the proportion of endoscopists whose follow-up recommendations were consistent with current guidelines for individuals meeting Amsterdam II criteria, and (iii) compare endoscopist and patient understanding of appropriate screening intervals.
METHODS

Study design
Study participants were enrolled in the Family Health Promotion Project (FHPP), a randomized controlled trial ( 19 ) designed with the primary aim of promoting colonoscopy adherence in members of high-risk CRC families; details of the FHPP study design have been previously published ( 19 ) . Briefl y, fi rst-degree family members unaff ected by CRC were recruited from two national cancer registries: the Colon Cancer Family Registry (CCFR) and the Cancer Genetics Network (CGN) ( 20 ) , which included individuals identifi ed by high-risk cancer clinics, as well as from populationbased cancer registries. Th ese registries collected detailed, threegeneration family histories. CRC-unaff ected family members identifi ed through these registries were sent a general newsletter regarding familial cancer risk and were invited to participate in FHPP. For the FHPP trial, these CRC-unaff ected participants were randomized to receive either an intensive tailored telephone and mailed counseling intervention (providing risk-specifi c, guideline-based colonoscopic screening recommendations of colonoscopy every 1-2 years for Amsterdam II participants) or to a control group that was mailed general information about the importance of cancer screening but no specifi c risk-based recommendations. Th e present analysis is restricted to the FHPP participants whose family met the Amsterdam II criteria (based on the three-generation family history obtained from the CFR and CGN).
All participants completed a baseline questionnaire prior to randomization and a follow-up questionnaire at 24 months. Th e baseline questionnaire evaluated participants' knowledge and uptake of genetic testing and knowledge of risk-appropriate colonoscopy screening intervals based on their personal risk. Th e 24-month follow-up questionnaire similarly assessed knowledge of recommended colonoscopy screening intervals, as well as adherence to colonoscopy screening during the study period.
Upon completion of the 24-month study period, a supplemental questionnaire was mailed to all participants who completed the FHPP study (2008) (2009) ) and included additional questions about how genetic testing was discussed between patients and providers and barriers to genetic testing.
Th e study was approved by the Colorado Multiple Institutional Review Board.
Study population
FHPP participants ( n =632) were recruited from nine CCFR and three CGN registry sites in the United States from 2004 to 2006, and were unaff ected by CRC, at least 21 years of age and English speaking. For this analysis, we included only those FHPP participants whose family met the Amsterdam II criteria ( n =165).
Study aims
Knowledge and uptake of genetic testing . Th e baseline questionnaire asked the following questions regarding the uptake of genetic counseling: "Have you ever heard of genetic testing for colon cancer, " "have any of your relatives had genetic testing, " "if yes, did any of them test positive, " "have you ever been advised to undergo genetic testing for colon cancer, " "have you ever had genetic testing for colon cancer, " and "if yes, did you test positive?" Th e supplemental questionnaire asked the following questions regarding genetic counseling: "Have you ever discussed genetic testing for colon cancer with your provider, if so, who raised the issue (I did, my doctor, other healthcare provider), " "have you ever been advised to consider genetic testing for colon cancer, if so, who advised you, " and "if you were advised to have genetic testing and did not, why did you choose not to be tested?" Knowledge and uptake of colonoscopic screening . Participant knowledge of CRC screening recommendations (based on guidelines for their level of risk) was evaluated by the following question asked at baseline and 24 months aft er the intervention: "How oft en should you have a colonoscopy performed? (responses: every 1-2 years; every 2-5 years, every 5-9 years; every 10 years or more). " A response of 'every 1-2 years' was considered to be a correct answer.
Adherence to colonoscopy screening was evaluated during follow-up as previously reported ( 21 ) . Participants who underwent colonoscopy at any time during the study period were asked to sign a medical release of information so that endoscopy reports, pathology reports, and medical chart documentation regarding endoscopy fi ndings and follow-up recommendations could be obtained. For this analysis, endoscopist screening interval recommendations were determined based on review of the endoscopy/ pathology reports and documentation in the patient chart.
Concordance between participant and endoscopist-perceived appropriate screening interval was evaluated by comparing individual endoscopist recommendations and participant responses as reported on the 24-month follow-up questionnaire.
Data management and statistical analysis
All data were analyzed using SAS Version 9.3 (SAS Institute, Carey, NC). Participant responses regarding knowledge of genetic counseling/testing and risk-appropriate screening intervals (dichotomous outcomes) were compared overall and according to participant recruitment source (clinic based vs. population based) using the χ 2 or Fisher's Exact test as appropriate. Concordance in participant-reported and endoscopist-reported recommendation of colonoscopy screening interval is reported as the proportion of responses in agreement and was assessed using the kappa statistic.
RESULTS
A total of 165 consenting participants from families who met Amsterdam II criteria were enrolled in FHPP, completed the baseline questionnaire, and were included in this study. Th ere was a 90% response rate for the 24-month follow-up questionnaire ( n =149) and a 55.2% response rate for the supplemental questionnaire ( n =91). Th ere were no diff erences in the participants who completed the follow-up questionnaire and supplemental questionnaire in terms of baseline characteristics, intervention group, or whether they were adherent to colonoscopy screening during the study.
Baseline characteristics
Baseline characteristics of the 165 participants included in this analysis are shown in Table 1 . Approximately 50% of participants were women, the majority were 50 years of age or older, Caucasian, had health insurance, a regular doctor, and incomes over $45,000. A little more than half of the participants (57%) were recruited into the FHPP study through a family member who was a patient in a high-risk cancer clinic vs. 43% who were recruited through a family member identifi ed by population-based cancer registries.
Participant knowledge and uptake of genetic testing
At baseline, 98% ( n =162) of participants reported that genetics or having a family history of CRC was "very important" ( n =125, 75.7%) or "important" ( n =37, 22.4%) in predicting future risk of colon cancer. Sixty-three percent ( n =104) had heard of genetic testing; signifi cantly more recruited from a high-risk clinic than those recruited from a population-based registry (71.3% ( n =67) vs. 52.1% ( n =37), P =0.015)). Only 31% ( n =51) of participants recalled being advised by a medical provider to undergo genetic testing ( Table 2 ) .
At baseline, only 7.3% ( n =12) had undergone genetic testing (8 reported testing positive and 4 reported testing negative). Twentyseven percent ( n =45) of the participants reported that a relative had undergone genetic testing, and 41.8% ( n =69) did not know whether a family member had been tested. Of those with family members who had undergone testing, 40.0% ( n =18/45) reported that their family member tested positive, 33.3% ( n =15/45) tested negative, and 26.7% ( n =12/45) did not know the results of their family member's testing. Th ere was no signifi cant diff erence in these responses according to recruitment source (population based vs. clinic based).
Of the 91 participants who completed the supplemental questionnaire, 24.2% ( n =22) reported having ever discussed genetic testing with their treating physicians; of these, 36% ( n =8) had raised the issue themselves, whereas 41% ( n =9) reported that their doctor had raised the issue. Th irty-three percent ( n =30) of those completing the supplemental questionnaire reported having been advised to undergo genetic testing by a variety of sources (13 from their doctor, 9 from another health-care provider, 7 from a family member, and one from a friend). Participants cited various barriers to undergoing genetic testing including that they could not aff ord it or insurance did not cover it ( n =10), that they were worried that their insurance company would fi nd out ( n =5), or that they have not made up their minds ( n =5); however, the most common response was that they were not advised to undergo genetic testing ( n =29).
Participant knowledge and uptake of colonoscopic screening
Participants' knowledge of appropriate colonoscopic screening interval at baseline and 24 months post randomization is shown in Table 3 . At baseline, only 21.8% of the participants reported 1-2 years as the appropriate colonoscopy screening interval given their family history of colon cancer with no diff erence between the participants recruited from a population-based registry or those recruited from a high-risk clinic.
At the end of the study (24 months), overall participant knowledge of risk-appropriate intervals increased only slightly to 25.5%. Th ere was a signifi cantly higher percentage of correct risk-based responses in the group recruited from high-risk clinics compared with population clinics at 24 months (35.1 vs. 12.7%, P =0.001). Th ere was no statistically signifi cant diff erence in correct riskbased responses when comparing other baseline characteristics. Despite the fact that the telephone intervention strongly emphasized the importance of colonoscopy every 1-2 years, there was no diff erence in the proportion of participants who reported 1-2 years as the appropriate screening interval between those who received the telephone counseling and tailored follow-up letter and those who were mailed general screening information (26 vs. 25%, respectively).
Ninety-fi ve (58%) participants had undergone colonoscopy screening during the 2-year study period. Th ere were a significantly higher proportion of participants recruited from a highrisk clinic who underwent colonoscopy when compared with participants recruited from population-based registries (63.8 vs. 49.2%, P =0.008), but there were no signifi cant diff erences in other baseline characteristics between participants who did and did not have screening.
Endoscopist recommendations for colonoscopic screening intervals
Colonoscopy and corresponding pathology reports were obtained from 83 of the 95 (87%) participants who reported having a colonoscopy during the study period. Th e indications for the procedure and follow-up recommendations are shown in Table 4 . On the basis of the colonoscopy reports, 20.5% ( n =17) listed Lynch syndrome or HNPCC as the primary indication for the procedure, 72.3% ( n =60) listed family history and/or personal history of CRC or polyps, and the remaining 8.4% ( n =7) listed routine screening, symptoms, or did not document the indication for the procedure.
Only 30.1% ( n =25/83) of the participants' endoscopists recommended repeating colonoscopy at the recommended interval for those who meet the Amsterdam II criteria (1-2 years), whereas 50.6% ( n =42/83) recommended a screening or surveillance interval of 3 to 5 years, and 17% ( n =14/83) did not document a follow-up recommendation. Of the 17 providers who listed "Lynch syndrome" or "HNPCC" as the indication for the procedure, 88% ( n =15) recommended 1-2-year follow-up colonoscopy.
Concordance between endoscopists and participants
Among the 83 participants with colonoscopy reports available, 69 had follow-up recommendations documented either in the report, in the medical chart, or on the pathology results sent to the participant. Th ree of these 69 were excluded from concordance analysis because of missing data from the participants' reports of 
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Impact of genetic testing results on colonoscopic indications and screening recommendations
Th e participants who reported that they had had genetic testing represent special groups. Th e four participants with known negative genetic testing would no longer fall into the 1-2-year screening category. Despite this, two of these four participants (and their corresponding endoscopists) still recommended that their next screening should be in 1-2 years. Th e other two thought it should be in 2-5 years. Excluding these four participants from the analysis did not signifi cantly alter the main results of the paper.
screening recommendations. A comparison of the participants' understanding of appropriate screening intervals (as reported on the 24-month follow-up survey) and the endoscopists' screening recommendations made at the time of colonoscopy is shown in Figure 1a . Th ere was a 65.2% (43/66) concordance ( Figure 1b ) between what the participant believed was the appropriate colorectal screening interval for themselves and what their endoscopist had recommended, corresponding to a weighted kappa statistic of 0.42 (95% CI 0.24-0.61) suggesting a fair-to-moderate agreement. Only 27.3% (18/66) of the participant/endoscopist pairs were in agreement that 1-2 years was the appropriate screening interval. Of the eight participants who reported testing positive for a Lynch syndrome mutation, fi ve thought that their next screening should be in 1-2 years, but only two of their endoscopists reported HNPCC or Lynch syndrome as the indication for the colonoscopy; these two endoscopists recommended a 1-2-year surveillance interval, the other six recommended a 3-5-year interval.
DISCUSSION
Lynch Syndrome is the most common hereditary CRC syndrome; yet, it is grossly under-recognized, resulting in missed opportunities to capture high-risk patients and their family members for appropriate genetic counseling and colonoscopic screening. Th e present study is one of the largest reports to date of the knowledge and uptake of genetic testing and guideline-based colonoscopic screening recommendations among CRC-unaff ected individuals who meet Amsterdam II criteria.
We found that, although the majority of participants acknowledged the importance of family history in CRC risk and had heard of genetic testing, <10% had undergone genetic testing. Further, only one-third of participants reported that their providers had advised them to undergo genetic testing, and a large proportion (27%) of participants who said that their family members had undergone genetic testing were unaware of the results. Th ese fi ndings demonstrate a major defi cit in guideline-based care for members of HNPCC families in the US and highlight the need to improve education of both providers and family members about the importance of the cancer family history as a tool to identify individuals at risk for a hereditary CRC syndrome. Th ese data also underscore the importance of communication about genetic test results within families in order to assure that at-risk members are provided adequate information about their familial risk of CRC.
Our results demonstrate very poor knowledge of and adherence to recommended colonoscopic screening intervals among both high-risk patients and their providers. Although knowledge of appropriate screening interval improved slightly among participants from baseline to 24 months, there appears to have been very little impact from the intensive telephone intervention despite the fact that participants received direct counseling that they should undergo colonoscopy every 1-2 years based on their level of risk. Th is suggests that education alone (at least that provided outside of the usual clinical setting) may not be suffi cient to change perceptions in individuals at increased risk. Our data suggest that the provider recommendation is a very important factor in participant understanding of screening intervals. Only 30% of the endoscopists for this high-risk population recommended colonoscopic screening every 1-2 years, and the concordance between what the endoscopist recom mended and what the participant reported as appropriate was moderate (65%). Th is would imply that patients are likely to adhere to what their provider recommends despite information provided through phone or mail-based interventions such as that used for FHPP and indicates that provider education is a critical element of any intervention to improve screening rates in this high-risk group.
Our fi ndings concur with those from a study by Stoff el et al. ( 22 ) that surveyed 181 patients from hereditary clinics in the US about their screening uptake. Twenty-seven percent of these patients had inadequate screening (≥1-2 years), and, of these, half had a colonoscopy within the last 3 to 5 years as per their doctors' recommendations, whereas only 24% reported that their provider had recommended 1-2 years. Th ese fi ndings along with those patients had a family history that met the Amsterdam II criteria. A much larger proportion of physicians listed "family history" as the indication for colonoscopy, suggesting that either the physicians were not aware of the full extent of the family history or that they did not recognize that the family history met the Amsterdam II criteria. Our data demonstrate a very low level of recognition of a potential hereditary syndrome among endoscopist for patients at-risk for Lynch syndrome. When providers recognized that their patients were from Lynch or HNPCC families, they were much more likely to recommend appropriate screening intervals. Th is suggests that a major reason that providers fail to recommend guideline-based screening is that they may not be aware (or may not recognize) that the patient meets Amsterdam II criteria. Lack of knowledge of current colonoscopic screening recommendations for HNPCC and Lynch Syndrome is likely a smaller contributor, as these guidelines are readily accessible and broadly endorsed by the gastroenterology community ( 5, 7, 8 ) .
Th is study has several strengths. It is one of the largest studies to assess knowledge of screening intervals among individuals meeting Amsterdam II criteria who are unaff ected by CRC. Th e data were collected systematically and prospectively as part of a randomized controlled trial in contrast to most studies of HNPCC/Lynch patients that rely on retrospective chart reviews (13) (14) (15) (16) (17) (18) 24 ) . Th e endoscopists' recommendations were collected from the medical record (endoscopy reports) rather than by physician surveys, which are less likely to capture true practice. An additional strength to our study is the inclusion of participants who met Amsterdam II criteria identifi ed through populationbased sources (43%). Th us, our results are more likely to refl ect the knowledge and practices of a greater population of persons at risk for Lynch syndrome than reports derived exclusively from high-risk clinics.
Th ere are also several limitations to our analyses. Th e participants were a selected cohort of mostly insured, educated, and affl uent individuals who had already been enrolled in a registry that focused on cancer family history. CRC screening knowledge is likely to be higher in this population than in the general population, suggesting that the problem of low level of knowledge of risk-appropriate guidelines might be even more pronounced in the general population than we found in this group. We were only able to evaluate endoscopist recommendations for participants who underwent colonoscopy during the study period. Th us, we were only able to obtain endoscopist surveillance recommendations from a subset ( n =83) of the total group ( n =165). However, we did not fi nd any signifi cant diff erences in baseline characteristics between those who had or did not have a colonoscopy. Genetic testing results were self-reported and not confi rmed by medical records. Th ere was a limited response in the supplemental questionnaire regarding how genetic testing discussions are initiated and barriers to obtaining genetic testing. Although there was no signifi cant diff erence in baseline characteristics between those who fi lled out the supplemental questionnaire and those who did not, we cannot ensure that these groups were equivalent in their attitudes. Negative genetic testing is reported in our study suggest that eff orts to improve adherence to recommended guidelines in potential Lynch families should include both patient and provider-directed strategies.
Participants who were recruited because their family member was being seen in a high-risk cancer clinic were about 20% more likely to report that they had heard of genetic testing and had discussed genetic testing with their provider, but this did not translate into higher rates of referral for or completion of genetic testing. Interestingly, although there was no diff erence at baseline, participants recruited from high-risk clinics exhibited signifi cantly better knowledge of appropriate screening intervals at 24 months aft er enrollment, regardless of whether they were in the minimal or intensive intervention group. Participants from high-risk clinics were also were more likely to be adherent to colonoscopic screening than those recruited from a population-based registry, again with no diff erence-based intervention group. Th is suggests that families who are seen at high-risk clinics are at an advantage in terms of risk recognition and can benefi t from the education and services provided by these clinics. In addition, it suggests that at-risk families in the population at-large, which constitute the majority of Lynch families, are not getting the information that they need to reduce their CRC risk.
Th ere are likely multiple reasons for the low level of knowledge about risk-appropriate colonoscopy screening guidelines among high-risk persons, but in this population it does not appear to be due to a lack of awareness of the importance of family history as a risk factor for CRC, or due to a lack of interest or concern about cancer risk, or a lack of awareness of the importance of CRC screening. We previously reported that approximately 90% of the participants in FHPP who met Amsterdam II criteria recognized that their family history of CRC increased their own risk, 80% were concerned about getting CRC, and 95% thought that CRC screening was part of good overall health care ( 19 ) . Possible contributing factors may include lack of awareness of diff erent risk categories (Amsterdam II criteria vs. other family history), limited family communication about risk, screening behavior of other family members, and the overall media and physician emphasis on promoting recommendations for the average risk population with less attention focused on high-risk groups. Although FHPP participants, particularly those recruited via population-based sources, generally recognized that they are at increased risk due to their family history, many may not have known that their family history was suggestive of a hereditary syndrome.
Th e reasons for the low level of appropriate screening recommendations (30%) by providers are also likely multi-factorial, but failure to recognize that patients meet Amsterdam II criteria is likely a major contributor. Lynch syndrome is grossly under-recognized ( 10 ) in part because providers oft en do not have access to a full family history ( 23 ) . Th is is more likely to be an issue in open access endoscopy units where the patients are not seen by the endoscopist prior to the procedure. In our study, Lynch syndrome or HNPCC was listed as the indication for the procedure in only 20% of the colonoscopy reports, despite the fact that all of the unlikely to have infl uenced participants/endoscopists knowledge of surveillance intervals, as the overall results of knowledge were no diff erent when the participants who reported testing negative were excluded.
In summary, this analysis demonstrates that individuals meeting Amsterdam II criteria are not oft en advised to have genetic testing and those who are have low uptake of genetic testing. In this experience, participants meeting Amsterdam II criteria have poor knowledge of appropriate screening guidelines, and their endoscopists do not appear to recognize their increased risk and typically do not recommend appropriate screening intervals. Patients, even those who received an intervention recommending evidence-based screening intervals, tended to agree with their providers' follow-up recommendations rather than those provided by our intervention. Th ese results highlight the possible futility of interventions directed to individuals that are not part of their medical care, as well as the importance of using multi-targeted approaches that include educational interventions for both providers and patients in order to improve recognition, screening, and surveillance of individuals at risk for Lynch syndrome.
